ID   J82
AC   CVCL_0359
SY   J-82; J 82; J82COT; J82 COT
DR   BTO; BTO:0001671
DR   CLO; CLO_0007006
DR   EFO; EFO_0002210
DR   MCCL; MCC:0000253
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-1
DR   BioSample; SAMN03471085
DR   BioSample; SAMN10987788
DR   CCLE; J82_URINARY_TRACT
DR   CCRID; 3111C0001CCC000346
DR   CCRID; 3131C0001000700218
DR   CCRID; 3131C0001001200024
DR   CCTCC; GDC0225
DR   Cell_Model_Passport; SIDM00693
DR   ChEMBL-Cells; CHEMBL3308508
DR   ChEMBL-Targets; CHEMBL614586
DR   Cosmic; 753566
DR   Cosmic; 755399
DR   Cosmic; 760474
DR   Cosmic; 808517
DR   Cosmic; 809378
DR   Cosmic; 845571
DR   Cosmic; 846276
DR   Cosmic; 867838
DR   Cosmic; 943731
DR   Cosmic; 1016887
DR   Cosmic; 1046674
DR   Cosmic; 1093984
DR   Cosmic; 1175827
DR   Cosmic; 1285119
DR   Cosmic; 1285996
DR   Cosmic; 1302362
DR   Cosmic; 1927308
DR   Cosmic; 1995459
DR   Cosmic; 2050445
DR   Cosmic; 2057450
DR   Cosmic; 2444229
DR   Cosmic; 2686097
DR   Cosmic; 2700997
DR   Cosmic-CLP; 753566
DR   DepMap; ACH-000396
DR   GDSC; 753566
DR   GEO; GSM136231
DR   GEO; GSM492491
DR   GEO; GSM827204
DR   GEO; GSM887167
DR   GEO; GSM888239
DR   GEO; GSM1374575
DR   GEO; GSM1574579
DR   GEO; GSM1669946
DR   IARC_TP53; 3721
DR   IARC_TP53; 21416
DR   IGRhCellID; J82
DR   KCB; KCB 2014052YJ
DR   KCLB; 30001
DR   LiGeA; CCLE_551
DR   LINCS_LDP; LCL-1714
DR   PharmacoDB; J82_675_2019
DR   Progenetix; CVCL_0359
DR   Wikidata; Q54898490
RX   PubMed=571047;
RX   PubMed=833871;
RX   PubMed=864752;
RX   PubMed=870558;
RX   PubMed=2594029;
RX   PubMed=3413074;
RX   PubMed=3518877;
RX   PubMed=3708594;
RX   PubMed=6220172;
RX   PubMed=6244232;
RX   PubMed=6582512;
RX   PubMed=6823318;
RX   PubMed=7787250;
RX   PubMed=9850064;
RX   PubMed=11921286;
RX   PubMed=12127398;
RX   PubMed=14762065;
RX   PubMed=15846775;
RX   PubMed=16885334;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=23401075;
RX   PubMed=24035680;
RX   PubMed=24367658;
RX   PubMed=25997541;
RX   PubMed=27270441;
RX   PubMed=27397505;
RX   PubMed=29732388;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/j/cell-lines-detail-250.html
WW   https://www.synapse.org/UC25
CC   Part of: BLA-40 bladder carcinoma cell line panel.
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: PTEN genetic alteration cell panel (ATCC TCP-1030).
CC   Part of: UBC-40 urothelial bladder cancer cell line index.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser770Pro (c.2308T>C); ClinVar=VCV000140988; Zygosity=Heterozygous (CCLE; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro124Leu (c.371C>T); Zygosity=Heterozygous (ATCC; CCLE; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn212fs*1 (c.635_1212del578); Zygosity=Homozygous (ATCC).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.2107-2A>G; ClinVar=VCV000013077; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=2594029; ATCC; CCLE; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu271Lys (c.811G>A); ClinVar=VCV000406566; Zygosity=Homozygous (PubMed=7787250; PubMed=9850064; ATCC).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys320Asn (c.960G>C); Zygosity=Heterozygous (PubMed=7787250; PubMed=9850064; ATCC).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.13%; Native American=0%; East Asian, North=2.62%; East Asian, South=0%; South Asian=0.42%; European, North=70.61%; European, South=26.21% (PubMed=30894373).
ST   Source(s): ATCC; CCRID; Cosmic-CLP; KCLB; PubMed=11416159; PubMed=27270441
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 10,12 (ATCC; CCRID; Cosmic-CLP; KCLB)
ST   D13S317: 12 (PubMed=27270441)
ST   D16S539: 11,12
ST   D18S51: 12
ST   D19S433: 12,13
ST   D21S11: 30 (CCRID)
ST   D21S11: 30,31 (PubMed=11416159)
ST   D2S1338: 19
ST   D3S1358: 16,18
ST   D5S818: 12,13
ST   D7S820: 9,11
ST   D8S1179: 8,13
ST   FGA: 20,24
ST   TH01: 9.3
ST   TPOX: 11,12
ST   vWA: 17,18
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_5H97 ! J82-EBV
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 34
//
RX   PubMed=571047;
RA   Fogh J.;
RT   "Cultivation, characterization, and identification of human tumor
RT   cells with emphasis on kidney, testis, and bladder tumors.";
RL   Natl. Cancer Inst. Monogr. 49:5-9(1978).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=864752; DOI=10.1093/jnci/58.6.1743;
RA   Marshall C.J., Franks L.M., Carbonell A.W.;
RT   "Markers of neoplastic transformation in epithelial cell lines derived
RT   from human carcinomas.";
RL   J. Natl. Cancer Inst. 58:1743-1751(1977).
//
RX   PubMed=870558; DOI=10.1177/25.4.870558;
RA   Benham F.J., Cottell D.C., Franks L.M., Wilson P.D.;
RT   "Alkaline phosphatase activity in human bladder tumor cell lines.";
RL   J. Histochem. Cytochem. 25:266-274(1977).
//
RX   PubMed=2594029; DOI=10.1056/NEJM198912213212501;
RA   Yandell D.W., Campbell T.A., Dayton S.H., Petersen R., Walton D.,
RA   Little J.B., McConkie-Rosell A., Buckley E.G., Dryja T.P.;
RT   "Oncogenic point mutations in the human retinoblastoma gene: their
RT   application to genetic counseling.";
RL   N. Engl. J. Med. 321:1689-1695(1989).
//
RX   PubMed=3413074; DOI=10.1073/pnas.85.16.6042;
RA   Pereira-Smith O.M., Smith J.R.;
RT   "Genetic analysis of indefinite division in human cells:
RT   identification of four complementation groups.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:6042-6046(1988).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=3708594;
RA   Masters J.R.W., Hepburn P.J., Walker L., Highman W.J.,
RA   Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.R.,
RA   Franks L.M.;
RT   "Tissue culture model of transitional cell carcinoma: characterization
RT   of twenty-two human urothelial cell lines.";
RL   Cancer Res. 46:3630-3636(1986).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=6244232;
RA   Williams R.D.;
RT   "Human urologic cancer cell lines.";
RL   Invest. Urol. 17:359-363(1980).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=6823318; DOI=10.1038/301429a0;
RA   O'Toole C.M., Povey S., Hepburn P.J., Franks L.M.;
RT   "Identity of some human bladder cancer cell lines.";
RL   Nature 301:429-430(1983).
//
RX   PubMed=7787250;
RA   Cooper M.J., Haluschak J.J., Johnson D., Schwartz S., Morrison L.J.,
RA   Lippa M., Hatzivassiliou G., Tan J.;
RT   "p53 mutations in bladder carcinoma cell lines.";
RL   Oncol. Res. 6:569-579(1994).
//
RX   PubMed=9850064;
RA   Markl I.D.C., Jones P.A.;
RT   "Presence and location of TP53 mutation determines pattern of
RT   CDKN2A/ARF pathway inactivation in bladder cancer.";
RL   Cancer Res. 58:5348-5353(1998).
//
RX   PubMed=11921286; DOI=10.1002/gcc.10050;
RA   Williams S.V., Sibley K.D., Davies A.M., Nishiyama H., Hornigold N.,
RA   Coulter J., Kennedy W.J., Skilleter A., Habuchi T., Knowles M.A.;
RT   "Molecular genetic analysis of chromosome 9 candidate tumor-suppressor
RT   loci in bladder cancer cell lines.";
RL   Genes Chromosomes Cancer 34:86-96(2002).
//
RX   PubMed=12127398; DOI=10.1016/S0165-4608(01)00648-3;
RA   Strefford J.C., Lillington D.M., Steggall M., Lane T.M., Nouri A.M.E.,
RA   Young B.D., Oliver R.T.D.;
RT   "Novel chromosome findings in bladder cancer cell lines detected with
RT   multiplex fluorescence in situ hybridization.";
RL   Cancer Genet. Cytogenet. 135:139-146(2002).
//
RX   PubMed=14762065; DOI=10.1101/gr.2012304;
RA   Bignell G.R., Huang J., Greshock J., Watt S., Butler A., West S.,
RA   Grigorova M., Jones K.W., Wei W., Stratton M.R., Futreal P.A.,
RA   Weber B., Shapero M.H., Wooster R.;
RT   "High-resolution analysis of DNA copy number using oligonucleotide
RT   microarrays.";
RL   Genome Res. 14:287-295(2004).
//
RX   PubMed=15846775; DOI=10.1002/gcc.20166;
RA   Williams S.V., Adams J., Coulter J., Summersgill B.M., Shipley J.M.,
RA   Knowles M.A.;
RT   "Assessment by M-FISH of karyotypic complexity and cytogenetic
RT   evolution in bladder cancer in vitro.";
RL   Genes Chromosomes Cancer 43:315-328(2005).
//
RX   PubMed=16885334; DOI=10.1158/0008-5472.CAN-06-1182;
RA   Lopez-Knowles E., Hernandez S., Malats N., Kogevinas M., Lloreta J.,
RA   Carrato A., Tardon A., Serra C., Real F.X.;
RT   "PIK3CA mutations are an early genetic alteration associated with
RT   FGFR3 mutations in superficial papillary bladder tumors.";
RL   Cancer Res. 66:7401-7404(2006).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23401075; DOI=10.1002/path.4176;
RA   Guo Y., Chekaluk Y., Zhang J., Du J., Gray N.S., Wu C.-L.,
RA   Kwiatkowski D.J.;
RT   "TSC1 involvement in bladder cancer: diverse effects and therapeutic
RT   implications.";
RL   J. Pathol. 230:17-27(2013).
//
RX   PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057;
RA   Hurst C.D., Platt F.M., Knowles M.A.;
RT   "Comprehensive mutation analysis of the TERT promoter in bladder
RT   cancer and detection of mutations in voided urine.";
RL   Eur. Urol. 65:367-369(2014).
//
RX   PubMed=24367658; DOI=10.1371/journal.pone.0084411;
RA   Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H.,
RA   Knowles M.A.;
RT   "Identification of mutations in distinct regions of p85 alpha in
RT   urothelial cancer.";
RL   PLoS ONE 8:E84411-E84411(2013).
//
RX   PubMed=25997541; DOI=10.1186/s12864-015-1450-3;
RA   Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B.,
RA   Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G.,
RA   Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D.,
RA   Chanock S.J., Valencia A., Real F.X.;
RT   "The UBC-40 Urothelial Bladder Cancer cell line index: a genomic
RT   resource for functional studies.";
RL   BMC Genomics 16:403.1-403.16(2015).
//
RX   PubMed=27270441; DOI=10.1038/onc.2016.172;
RA   Nickerson M.L., Witte N., Im K.M., Turan S., Owens C., Misner K.,
RA   Tsang S.X., Cai Z., Wu S., Dean M., Costello J.C., Theodorescu D.;
RT   "Molecular analysis of urothelial cancer cell lines for modeling tumor
RT   biology and drug response.";
RL   Oncogene 36:35-46(2017).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K.,
RA   Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//